Considering ERK1/2 are active in epithelial cancers, including breast cancer, if ERK1/2 requires autocrine activation of EGFR, than the therapeutic blockade of EGFR will block ERK1/2-driven tumorigenic responses. The gene discussed is MAPK3; the disease is breast cancer.